Voyager Therapeutics 获 FDA 批准 Vy1706 新药临床试验,开创阿尔茨海默病基因疗法新路径,旨在减少大脑 Tau 蛋白生成

美股速递
Jun 01

Voyager Therapeutics Inc 宣布,其创新基因疗法 Vy1706 已获得美国食品药品监督管理局(FDA)的新药临床试验(IND)批准。该疗法旨在通过降低大脑中 Tau 蛋白的生成来治疗阿尔茨海默病,标志着首款针对此病理机制的基因治疗策略进入临床开发阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10